PMID- 16805745
OWN - NLM
STAT- MEDLINE
DCOM- 20070405
LR  - 20220409
IS  - 1368-5031 (Print)
IS  - 1368-5031 (Linking)
VI  - 60
IP  - 6
DP  - 2006 Jun
TI  - Cardiac safety of rivastigmine in Lewy body and Parkinson's disease dementias.
PG  - 639-45
AB  - Cholinesterase inhibition in patients with Alzheimer's disease (AD) may affect 
      heart rate, sometimes inducing bradycardia. Additional cardiac safety 
      considerations apply in patients with dementia with Lewy bodies (DLB) and 
      Parkinson's disease (PDD), in whom cardiovascular autonomic nervous system 
      dysfunction is common. We conducted a review of the safety data available for 
      rivastigmine in these two conditions. A modest reduction in the mean heart rate 
      of 1.5-2 bpm was seen. No clinically meaningful treatment differences in 
      bradycardia or ECG abnormalities were apparent. Compared with placebo, 
      rivastigmine appeared to be associated with fewer vascular disorder adverse 
      events (AEs) (p = 0.002) and fewer AEs of syncope (p = 0.018) in PDD patients (n 
      = 541). A smaller randomised, placebo-controlled study of rivastigmine in DLB (n 
      = 120) showed similar findings. Rivastigmine appears to have a favourable cardiac 
      safety profile in PDD and DLB patients.
FAU - Ballard, C
AU  - Ballard C
AD  - King's College, London, UK. clive.ballard@kcl.ac.uk
FAU - Lane, R
AU  - Lane R
FAU - Barone, P
AU  - Barone P
FAU - Ferrara, R
AU  - Ferrara R
FAU - Tekin, S
AU  - Tekin S
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PL  - India
TA  - Int J Clin Pract
JT  - International journal of clinical practice
JID - 9712381
RN  - 0 (Cholinesterase Inhibitors)
RN  - 0 (Neuroprotective Agents)
RN  - 0 (Phenylcarbamates)
RN  - PKI06M3IW0 (Rivastigmine)
SB  - IM
EIN - Int J Clin Pract. 2006 Sep;60(9):1146
MH  - Aged
MH  - Aged, 80 and over
MH  - Cholinesterase Inhibitors/*adverse effects
MH  - Double-Blind Method
MH  - Female
MH  - Heart Diseases/*chemically induced
MH  - Humans
MH  - Lewy Body Disease/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Multicenter Studies as Topic
MH  - Neuroprotective Agents/*adverse effects
MH  - Parkinson Disease/*drug therapy
MH  - Phenylcarbamates/*adverse effects
MH  - Randomized Controlled Trials as Topic
MH  - Rivastigmine
EDAT- 2006/06/30 09:00
MHDA- 2007/04/06 09:00
CRDT- 2006/06/30 09:00
PHST- 2006/06/30 09:00 [pubmed]
PHST- 2007/04/06 09:00 [medline]
PHST- 2006/06/30 09:00 [entrez]
AID - IJCP967 [pii]
AID - 10.1111/j.1368-5031.2006.00967.x [doi]
PST - ppublish
SO  - Int J Clin Pract. 2006 Jun;60(6):639-45. doi: 10.1111/j.1368-5031.2006.00967.x.